According to three recent studies, which cancer type's survival trends are not impacted by racial disparities?

Conferences

By Reuters Staff

LONDON (Reuters) - British liquid biopsy company Angle said its Parsortix blood test had beaten current methods in identifying ovarian cancer, a breakthough that could help women receive the best possible outcome from surgery.

Read More

Patients treated with intensity-modulated radiation therapy (IMRT) for cervical or endometrial cancer have fewer adverse events and experience better quality of life than those treated with conventional radiation therapy (RT), according to research presented at the 2016 American Society for Radiation Oncology (ASTRO) Annual Meeting (September 25-28; Boston, MA).
-----

Read More

Prolonging platinum-free interval (PFI) by introducing non-platinum-based chemotherapy may actually worsen efficacy outcomes in patients with recurrent ovarian cancer, according to clinical trial results presented at the 2016 American Society of Clinical Oncology Annual Meeting in Chicago, IL (June 3-7).

Read More

News

Three recent studies have identified trends in survival for patients with ovarian, colon, and breast cancer in the United States based on race and disease stage.

A recent study found that treatment with PARP inhibitors significantly increases the risk of hematologic toxicities and warrants frequent clinical monitoring by clinicians.

Read More

The Institute for Clinical and Economic Review (ICER) confirmed in a recent report that evidence is lacking for outcomes comparisons of ploy-ADP ribose polymerase (PARP) inhibitors to treat ovarian cancer, and that prices should be lowered to increase affordability and patient access.

Read More

A recent study assessed the hypothesis that prolonging the platinum-free interval with platinum-free chemotherapy may offer improved outcomes in patients with progressing ovarian cancer, published in the Journal of Clinical Oncology (October 2017;35[29]:3347-3353).

Read More

Quiz

According to three recent studies, which cancer type's survival trends are not impacted by racial disparities?
Which PARP inhibitor was recently found to increase quality of life in patients with ovarian cancer?

Which PARP inhibitor was recently found to increase quality of life in patients with ovarian cancer?

-----

A. Rucaparib

B. Olaparib

C. Niraparib

D. Veliparib

-----

See the answer here.

Read More

Research in Review

Women with advanced ovarian cancer who express a certain tumor antigen will likely experience a shorter progression-free survival (PFS) and overall survival (OS) than those without the antigen, according to research published in Gynecologic Oncology (June 2017;145[3]:420-425).

-----

Related Content

Read More

The treatment landscape in the coming decade for ovarian cancers will likely feature poly ADP ribose polymerase (PARP) inhibitors in combination with other treatments, according to reports from a recent conference.

-----

Related Content

Read More

Women with BRCA-mutated relapsed serous ovarian cancer who received maintenance therapy after platinum-based chemotherapy prolonged their progression-free survival (PFS) by almost 7 months, according to results of a study presented at the 2017 ASCO Annual Meeting (June 2-6, 2017; Chicago, IL).

-----

Related Content

Read More

Patients receiving treatment for ovarian cancer experienced a significant out-of-pocket financial burden, due largely to cost disparities across treatment types and a lack of definitive treatment options, according to research presented at the 2017 ASCO Annual Meeting (June 2-6, 2017; Chicago, IL).

-----

Related Content

Read More

Subscribe to Ovarian Cancer